Search

Background and Objectives: The HALP (Haemoglobin, Albumin, Lymphocyte and Platelet) score is used to predict the prognosis of different types of cancer. This study aimed to investigate the role of the HALP score in predicting pathological response in early-stage gastric cancer patients. Materials and Methods: This retrospective cohort study was conducted on 118 patients diagnosed with early-stage gastric cancer and subjected to perioperative (FLOT) treatment between 2018 and 2023. The role of the HALP score in predicting the pathological response to perioperative treatment in patients was investigated. Results: The mean age of the 118 patients included in the study was 61.3 ± 11.1 (min = 23; max = 86). In the ROC analysis, the optimum cut-off value for the HALP score in pathological response classification was found to be 28.9 (AUC = 0.710, sensitivity = 56.7%, specificity = 80%, PPV = 86.79%, NPV = 46.15%). The pathological response rate was 69% in all patients, 87% in patients with a HALP score ≥ 28.9, and 52% in patients with a HALP score < 28.9 (p < 0.001). The probability of pathological response is 6.5 times higher in patients with a HALP score ≥ 28.9. In the Fagan nomogram, when the HALP score was ≥28.9, our pathological response probability estimate (post-test response probability) was found to increase to 64.8% (Positive Likelihood Ratio = 3, Negative Likelihood Ratio = 0.53). In patients with HALP scores ≥ 28.9 and p < 0.001), and median survival times were 45.4 and 30.6 months (p < 0.001). Conclusions: The HALP score is a useful and easily accessible score for determining pathological responses in patients with locally advanced gastric cancer.

Aim:Around 40% of non-small cell lung cancers have stage 3b or 4 disease at the time of diagnosis. In the treatment, platinum-based therapy can still be used in patients who do not carry a driver mutation or who are not suitable for immunotherapy with advanced non-small cell lung cancers (NSCLC). The objective of this study was to compare the effectiveness of weekly carboplatin-paclitaxel regimen with triweekly carboplatin-paclitaxel regimen.Materials and Methods:This is a retrospectively structured study. Patients who were followed-up and treated for lung cancer in Adana City Training and Research Hospital’s Oncology Department between January 1, 2017 and July 1, 2021 were included.Results:Out of the 104 patients, 52 (50%) patients received weekly carboplatin-paclitaxel (C-P), and 52 (50%) received C-P every 3 weeks. The mean overall survival was 19.64±2.53 months in the weekly C-P group and 17.47±1.64 months in the triweekly C-P group (p=0.675). The mean progression-free survival (PFS) was 8.5±1.01 months in the weekly C-P group and 5.76±0.61 months in the triweekly C-P group (p=0.017).Conclusion:We demonstrated that weekly C-P treatment, which is known to have fewer toxicity in NSCLC, provided better PFS compared to triweekly treatment.

Abstract Introduction Approximately 20–33% of all cancer patients are treated with acid-reducing agents (ARAs), most commonly proton pump inhibitors (PPIs), to reduce gastroesophageal reflux disease symptoms. Palbociclib and ribociclib are weak bases so their solubility depends on different pH. The solubility of palbociclib dramatically decreases to

Purpose: Testicular cancer is the most common solid tumor in young men between the ages of 20-35 and has excellent clinical outcomes with appropriate treatment. Neutrophil-to-lymphocyte-ratio (NLR) is related with prognosis and relapse in different solid tumors. We aimed to investigate the relation of presence and size of regional lymph node metastasis with NLR in testicular cancer. Materials and Methods: A total of 72 testicular cancer patients were included in the study. All medical records were retrospectively collected. NLR was calculated as the count of neutrophil divided by the count of lymphocyte. Chest and abdomen computed tomograpy (CT) scans of all patients were evaluated for metastases. Results: The mean age was 32.18±8.89 years. The pathologic classification was seminoma in 43% and nonseminoma in 57% of patients. Of 72 patients, 32 (44.4%) had lymph node positivity and 40 (55.6%) hadnot. The mean NLR value was 2.63±1.79 for all cohort. The mean NLR was significantly lower in patients with lymph node negative disease (for lymph node positive and negative disease 3.19±2.32 and 2.25±1.06, respectively.). In the ROC analysis, 2.5 was determined as the cut-off value for NLR to assess lymph node status. Conclusion NLR is a cheap and readily available index that can be used to determine lymph node metastases in testicular GCTs.

Amaç: Bu çalışmanın amacı kanser hastalarında koronavirus hastalığı 2019 (coronavirus disease 2019, COVID-19) bilgisayarlı tomografi (BT), klinik ve laboratuvar bulgularının değerlendirilmesi ve polimeraz zincir reaksiyonu (polymerase chain reaction, PCR) pozitif ve negatif hastaların bulgularının karşılaştırılmasıdır. Gereç ve Yöntemler: Çalışmaya PCR testi pozitif olan 23, klinik ve radyolojik bulgularla COVID-19 tanısı almış 22 kanser hastası alındı. Hastaların BT görüntüleri iki radyolog tarafından eşzamanlı değerlendirildi. Komorbid hastalık varlığı, semptomlar ve laboratuvar değerleri değerlendirildi. Bulgular: En sık BT tutulum paterni %88,9 (n=40) ile periferaldi. Bilateral akciğer tutulumu oranı %57,8 (n=26) idi. En sık saptanan bulgu buzlu cam dansiteleri idi (n=38, %84,5). Bunların %35,5 (n=16)’ine konsolidasyon da eşlik etmekteydi. Vakaların %62,2 (n=28)’sinde multifokal tutulum mevcuttu. En sık tutulan loblar alt loblar idi. Diğer nispeten sık bulgular septal kalınlaşma, subplevral çizgilenme ve hava bronkogramı idi. Hastaların ortanca nötrofil, lenfosit, D-dimer, prokalsitonin, C-reaktif protein ve laktat dehidrogenaz değerleri sırasıyla 2000 mm3, 1200 mm3, 1990 ng/mL, 30.7 µg/L 15.8 mg/dl, 161 IU/L idi. Sonuç: Multifokal ve bilateral tutulum ile buzlucam dansiteleri en sık bulgulardı. Ancak genelde daha az saptanan septal kalınlaşmanın yüksek saptanması kanser hastalarında bulguların daha ciddi olabileceğini düşündürmektedir. PCR negatif vakalarda inflamatuvar markerların birçoğu daha yüksekti. Çok merkezde daha fazla hasta ile yapılacak çalışmalar kanser hastalarındaki bulguları genel popülasyonla daha iyi karşılaştırmayı sağlayacaktır.

Amaç: Bu çalışmada bir Üniversite Dahiliye Yoğun Bakım Ünitesinde (DYBÜ) trombositopeni sıklığı, nedenleri, klinik sonuçları ile mortalite ve morbiditeye olan katkısını saptamayı amaçladık.Gereç ve Yöntemler: Temmuz 2011-Ağustos 2012 tarihleri arasında yoğun bakımda takip edilen vetrombosit sayısı 150.000/uL’nin altında olan 165 hasta çalışmaya dahil edildi. Trombositopeni nedenleri araştırıldı. Trombositopenisi olan ve trombositopenisi olmayan hastaların mortalite ve yoğun bakım yatış sürelerikarşılaştırıldı.Bulgular: Çalışma döneminde DYBÜ’de hastaların %30,1’inde trombositopeni gelişti (165/548). Hastaların 30 (%18)’unda trombositopeni nedeni sepsis, 18 (%10,9)’inde dissemine intravasküler koagülasyon (DİK) idi. Çalışma süresince 165 trombositopenik hastanın 115’i (%69,7), trombositopenik olmayan 383 hastanın 173’ü (%45,1) kaybedildi. Trombositopenisi olan hastalarda mortalite daha fazlaydı. Hastalarda trombosit düzeyi düştükçe mortalitenin istatistiksel olarak anlamlı düzeyde arttığı gözlendi. Aynı APACHE II skoruna sahip hasta gruplarında trombosit sayısı düştükçe mortalitenin istatistiksel olarak anlamlı olarak arttığı saptandı.Sonuç: Trombositopeninin en sık sebepleri sepsis ve DİK olup trombositopeni yoğun bakımda mortaliteyi arttıran bir etkendir.

İntroduction: Patients cured of any cancer have an increased risk of developing a new primary malignancy compared to the general population. However, synchronous presentation of two tumours is a very rare condition. Here we aim to review the treatment approach of a case of synchronous mantle cell lymphoma and invasive ductal carcinoma of the breast. Case Report: A 64-year-old woman presented with a right breast mass. Physical examination revealed a 3cm diameter mass lesion in the right breast and lymphadenopathy in the right axilla. Her past medical history was unremarkable except hypertension. In her family history, there was a history of breast cancer in her niece. Breast ultrasonography revealed 3 centimetres (cm) of malignant breast and multiple lymph nodes with thick cortex in bilateral axillae with indistinguishable fatty hilus. Tru-cut biopsy was performed for the mass in the breast and bilateral axilla lymph nodes. The breast biopsy was compatible with invasive ductal carcinoma with ER 90%, PR 10%, her2 negative and Ki67 proliferation index 10%. Bilateral axilla lymph node biopsy was reported as mantle cell lymphoma and immunohistochemically CD20: Positive, CD5: Positive, Cyclin D1: Positive, CD23: Negative, Lef1: Negative, Keratin: Negative, Ki67 proliferation index 25-30%. PET-CT revealed a mass in the right breast, lymph nodes with pathological appearance in the axillae, various lymph node stations in the abdomen and inguinal areas, and diffuse involvement suggestive of lymphoma infiltration in the right lung. Bone marrow aspiration/biopsy revealed mantle cell lymphoma involvement. The patient was discussed in the multidisciplinary tumour council and right axillary lymph node dissection was performed for staging. 5 lymph nodes showed ductal carcinoma metastasis and the rest of the lymph nodes showed mantle cell lymphoma involvement. Stage IV MHL and hormone positive IDC (T2N2) were detected and R-CHOP treatment was applied. PET-CT performed after three cycles of treatment showed complete response. The patient was discussed again in the multidisciplinary tumour council and surgical treatment for the breast was planned after completing 6 cycles of R-CHOP treatment. After treatment, the patient underwent modified radical mastectomy and the pathological stage was T3N3. After adjuvant RT, endocrine therapy was started and the patient is being followed in remission. Conclusion: Coexistence of breast cancer and mantle cell lymphoma is a rare condition. In the few cases reported in the literature, treatment planning was made by considering the stage and treatment priority of both diseases. We planned to prioritise the treatment of lymphoma because our patient had stage 4 mantle cell lymphoma.

(1) Background: The introduction of novel therapies has led to a considerable evolution in the management of Multiple Myeloma, and chromosomal abnormalities predict the success of treatment. We aimed to characterize cytogenetic abnormalities for risk stratification in the patient population and to evaluate the predictive and prognostic value of the specified abnormalities in distinct treatment modalities. (2) Methods: This study included patients with Multiple Myeloma who applied to the Internal Medicine Clinic of the Cukurova University Faculty of Medicine. Between 2010 and 2023, 98 cases with cytogenetic abnormality data were identified. We analysed the effects of cytogenetic abnormalities on survival and response rates to first chemotherapies. (3) Results: P53 del was the most prevalent abnormality, and t(11;14) was the most common translocation. There was no significant difference in the mean survival and treatment response rates for specific cytogenetic abnormalities. When chemotherapies based on lenalidomide were initiated, patients’ life-death statuses differed significantly from those of treatments without lenalidomide. Regardless of the type of chromosomal aberration, lenalidomide-based treatments independently enhanced average survival 14-fold, while there was no significant difference in overall survival among treatments. (4) Conclusions: In individuals with cytogenetic abnormalities, lenalidomide-based treatments should be started regardless of the chemotherapy to be used for the condition.

Background and Objective: This study evaluated the relationship between microsatellite status (MSI) and pan-immune-inflammation score (PIV) in tumor response to neoadjuvant chemotherapy (NAC) in patients with clinical stage III gastric cancer (cStage III GC). Materials and Methods: Microsatellite instability (MSI) status was evaluated based on pathology preparations. Pan-immune-inflammation score (PIV) was obtained from pre-treatment blood tests. The relationship of both parameters with pathological complete response (pCR) was evaluated. Results: A total of 104 patients were included in this study. All the patients were stage III GC patients receiving perioperative treatment. There were 13 patients in total who achieved a pCR response. While CNS was detected in 11 of the patients who achieved a pCR, the MSI status of the other two patients was unknown. No pCR was observed in any patient with MSI-H. According to the cut-off value for PIV, 25 (24%) patients were in the PIV-low (≤53.9) group, while 79 (76%) were in the PIV-high (>53.9) group. Based on univariate analysis, a higher PIV was associated with worse outcomes for pathological response, disease recurrence, and survival (p < 0.05). Conclusions: In patients with clinically stage III GC, the presence of MSI-H may predict no benefit from perioperative treatment. Conversely, a pre-treatment PIV score using specific cut-off values may provide a positive prediction of pathological response and survival.